Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 13/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397900 | 0.79 | QPCT (0.46) | QPCTDRD4DRD3TMEM97SIGMAR1 | |
| SCHEMBL2394839 | 0.74 | QPCT (0.51) | QPCT | |
| SCHEMBL2398225 | 0.72 | QPCT (0.46) | QPCT | |
| SCHEMBL2395058 | 0.71 | QPCT (0.84) | QPCT | |
| SCHEMBL2400136 | 0.71 | QPCT (0.52) | QPCT | |
| SCHEMBL2395930 | 0.69 | QPCT (0.52) | QPCT | |
| SCHEMBL2397934 | 0.68 | QPCT (0.67) | QPCT | |
| SCHEMBL2397397 | 0.68 | QPCT (0.85) | QPCT | |
| SCHEMBL2397607 | 0.67 | QPCT (0.82) | QPCT | |
| SCHEMBL3034900 | 0.66 | TEK (0.43) | DRD4DRD3TMEM97SIGMAR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | QPCT 1/4885GSK3B 1270/4885DRD4 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.